Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ analysis
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Clinical Trials, Phase IV as Topic
Cytokines
/ metabolism
Epidermal Growth Factor
/ metabolism
Humans
Lung Neoplasms
/ drug therapy
Lymphocyte Subsets
/ immunology
Prognosis
B cells
Epidermal growth factor
Pro-inflammatory cytokines
T cells
Terminally differentiated T cells
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
17
07
2020
accepted:
07
12
2020
pubmed:
4
1
2021
medline:
1
6
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
Aging is considered the single most significant risk factor for the majority of common malignances including lung cancer. Together immunosenescence, changes occurring with aging in the immune system, and inflammaging, characterizes by a chronic, subclinical accumulation of pro-inflammatory factors, are suggested to stand at the origin of most of the diseases of the elderly, such as cancer. The aim of this study was to determine associations among lymphocyte subpopulations, pro-inflammatory cytokines and epidermal growth factor (EGF) in patients diagnosed with non-small cell lung cancer (NSCLC). Forty-six advanced NSCLC patients were enrolled. Sixteen patients with newly diagnosed and before treatment and 30 patients after first-line platinum-based chemotherapy. Peripheral blood subpopulations were studied by flow cytometry and serum concentrations of soluble factors by ELISA. The frequency of naïve CD4
Identifiants
pubmed: 33388995
doi: 10.1007/s00262-020-02823-1
pii: 10.1007/s00262-020-02823-1
doi:
Substances chimiques
Biomarkers, Tumor
0
Cytokines
0
Epidermal Growth Factor
62229-50-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1735-1743Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
Salud, Aed (2019) Cuba: Ministerio de Salud Pública. Dirección de registros médicos y estadísticas de salud.
Miller, KD; Nogueira L; Mariotto AB; Rowland JH; Yabroff KR; Alfano CM; Jemal A; Kramer JL; Siegel RL (2019) Cancer treatment and survivorship statistics, 2019. CA: a cancer journal for clinicians 69:363–85. https://doi.org/10.3322/caac.21565
Health, WO (Feb 3, 2014) Lyon, France: International Agency for Research on Cancer. Press Release No. 224. Available from: http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf .
Aunan JR, Cho WC, Soreide K (2017) The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks. Aging Dis 8:628–642. https://doi.org/10.14336/AD.2017.0103
doi: 10.14336/AD.2017.0103
pubmed: 28966806
pmcid: 5614326
Fulop T, Larbi A, Kotb R, Pawelec G (2013) Immunology of aging and cancer development. Interdiscip Topics Gerontol 38:38–48. https://doi.org/10.1159/000343599
doi: 10.1159/000343599
Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G (2000) Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244–254. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x
doi: 10.1111/j.1749-6632.2000.tb06651.x
pubmed: 10911963
Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C (2017) Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol 8:1960. https://doi.org/10.3389/fimmu.2017.01960
doi: 10.3389/fimmu.2017.01960
pubmed: 29375577
Nevalainen T, Autio A, Kummola L, Salomaa T, Junttila I, Jylha M, Hurme M (2019) CD27− IgD− B cell memory subset associates with inflammation and frailty in elderly individuals but only in males. Immun Ageing 16:19. https://doi.org/10.1186/s12979-019-0159-6
doi: 10.1186/s12979-019-0159-6
pubmed: 31423147
pmcid: 6693136
Zhang X, Meng X, Chen Y, Leng SX, Zhang H (2017) The biology of aging and cancer: frailty, inflammation, and immunity. Cancer J 23:201–205. https://doi.org/10.1097/PPO.0000000000000270
doi: 10.1097/PPO.0000000000000270
pubmed: 28731941
Ding ZC, Zhou G (2012) Cytotoxic chemotherapy and CD4
doi: 10.1155/2012/890178
pubmed: 22400040
pmcid: 3286900
Onyema OO, Decoster L, Njemini R, Forti LN, Bautmans I, De Waele M, Mets T (2015) Chemotherapy-induced changes and immunosenescence of CD8
pubmed: 25750301
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Garcia Verdecia B, Saavedra Hernandez D, Lorenzo-Luaces P, de Jesus Badia Alvarez T, Leonard Rupale I, Mazorra Herrera Z, Crombet Ramos T, Lage Davila A (2013) Immunosenescence and gender: a study in healthy Cubans. Immun Ageing 10:16. https://doi.org/10.1186/1742-4933-10-16
doi: 10.1186/1742-4933-10-16
pubmed: 23627933
pmcid: 3667016
Saavedra D, Garcia B, Lorenzo-Luaces P, Gonzalez A, Popa X, Fuentes KP, Mazorra Z, Crombet T, Neninger E, Lage A (2016) Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. Cancer Immunol Immunother 65:37–45. https://doi.org/10.1007/s00262-015-1773-6
doi: 10.1007/s00262-015-1773-6
pubmed: 26589409
Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR (2016) Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res BCR 18:10. https://doi.org/10.1186/s13058-015-0669-x
doi: 10.1186/s13058-015-0669-x
pubmed: 26810608
Bailur JK, Pawelec G, Hatse S, Brouwers B, Smeets A, Neven P, Laenen A, Wildiers H, Shipp C (2017) Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast Cancer Res BCR 19:20. https://doi.org/10.1186/s13058-017-0813-x
doi: 10.1186/s13058-017-0813-x
pubmed: 28241844
Wu J, Waxman DJ (2018) Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett 419:210–221. https://doi.org/10.1016/j.canlet.2018.01.050
doi: 10.1016/j.canlet.2018.01.050
pubmed: 29414305
pmcid: 5818299
Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizee G, Radvanyi LG (2012) Detection and characterization of a novel subset of CD8(
doi: 10.1158/1078-0432.CCR-11-2034
pubmed: 22307139
pmcid: 3343210
Takayama E, Koike Y, Ohkawa T, Majima T, Fukasawa M, Shinomiya N, Yamaguchi T, Konishi M, Hiraide H, Tadakuma T, Seki S (2003) Functional and Vbeta repertoire characterization of human CD8
doi: 10.1046/j.1365-2567.2003.01575.x
pubmed: 12562330
pmcid: 1782888
Wu RC, Hwu P, Radvanyi LG (2012) New insights on the role of CD8(
doi: 10.4161/onci.20307
pubmed: 23162769
pmcid: 3489757
Pangrazzi L, Reidla J, Carmona Arana JA, Naismith E, Miggitsch C, Meryk A, Keller M, Krause AAN, Melzer FL, Trieb K, Schirmer M, Grubeck-Loebenstein B, Weinberger B (2020) CD28 and CD57 define four populations with distinct phenotypic properties within human CD8(
doi: 10.1002/eji.201948362
pubmed: 31755098
Larbi A, Fulop T (2014) From “truly naive” to “exhausted senescent” T cells: when markers predict functionality. Cytometry Part A J Int Soc Anal Cytol 85:25–35. https://doi.org/10.1002/cyto.a.22351
doi: 10.1002/cyto.a.22351
Bent R, Moll L, Grabbe S, Bros M (2018) Interleukin-1 beta—a friend or foe in malignancies? Int J Mol Sci. https://doi.org/10.3390/ijms19082155
doi: 10.3390/ijms19082155
pubmed: 30042333
pmcid: 6121377
Popa DG, Fuentes K, Huerta V, Alvarez K, Viada C, Neninger E, Rodríguez P, González Z, González A, Crombet T, Mazorra Z (2020) Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule. OncoImmunology 9(1):1762465. https://doi.org/10.1080/2162402X.2020.1762465
doi: 10.1080/2162402X.2020.1762465
pubmed: 32923124
pmcid: 7458606
Rodriguez PC, Popa X, Martinez O, Mendoza S, Santiesteban E, Crespo T, Amador RM, Fleytas R, Acosta SC, Otero Y, Romero GN, de la Torre A, Cala M, Arzuaga L, Vello L, Reyes D, Futiel N, Sabates T, Catala M, Flores YI, Garcia B, Viada C, Lorenzo-Luaces P, Marrero MA, Alonso L, Parra J, Aguilera N, Pomares Y, Sierra P, Rodriguez G, Mazorra Z, Lage A, Crombet T, Neninger E (2016) A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res Official J Am Assoc Cancer Res 22:3782–3790. https://doi.org/10.1158/1078-0432.CCR-15-0855
doi: 10.1158/1078-0432.CCR-15-0855
Saavedra D, Crombet T (2017) CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol 8:269. https://doi.org/10.3389/fimmu.2017.00269
doi: 10.3389/fimmu.2017.00269
pubmed: 28348561
pmcid: 5346887
Garcia B, Neninger E, de la Torre A, Leonard I, Martinez R, Viada C, Gonzalez G, Mazorra Z, Lage A, Crombet T (2008) Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14:840–846. https://doi.org/10.1158/1078-0432.CCR-07-1050
doi: 10.1158/1078-0432.CCR-07-1050
pubmed: 18245547
Meeuwsen JAL, van Duijvenvoorde A, Gohar A, Kozma MO, van de Weg SM, Gijsberts CM, Haitjema S, Bjorkbacka H, Fredrikson GN, de Borst GJ, den Ruijter HM, Pasterkamp G, Binder CJ, Hoefer IE, de Jager SCA (2017) High levels of (un)switched memory b cells are associated with better outcome in patients with advanced atherosclerotic disease. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.005747
doi: 10.1161/JAHA.117.005747
pubmed: 28882820
pmcid: 5634255
Saavedra D, Neninger E, Rodriguez C, Viada C, Mazorra Z, Lage A, Crombet T (2018) CIMAvax-EGF: toward long-term survival of advanced NSCLC. Semin Oncol 45:34–40. https://doi.org/10.1053/j.seminoncol.2018.04.009
doi: 10.1053/j.seminoncol.2018.04.009
pubmed: 30318082
Gonzalez G, Crombet T, Lage A (2011) Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment. Curr Cancer Drug Targets 11:103–110. https://doi.org/10.2174/156800911793743583
doi: 10.2174/156800911793743583
pubmed: 21062240